Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress

Pharmaceutical industry pricing practices will grab headlines Tuesday when several drug company CEOs appear before the U.S. Senate Finance Committee and the reigning top-selling drug Humira could be the featured attraction.